FibroGen Revenue and Competitors
Estimated Revenue & Valuation
- FibroGen's estimated annual revenue is currently $283.8M per year.
- FibroGen's estimated revenue per employee is $538,444
- FibroGen's total funding is $188M.
- FibroGen's current valuation is $1.3B. (January 2022)
Employee Data
- FibroGen has 527 Employees.
- FibroGen grew their employee count by -15% last year.
FibroGen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Executive Director, Business Development & Licensing | Reveal Email/Phone |
4 | Chief People Officer | Reveal Email/Phone |
5 | SVP, China Operations | Reveal Email/Phone |
6 | VP Information Technology | Reveal Email/Phone |
7 | VP Intellectual Property | Reveal Email/Phone |
8 | Head Customer Experience | Reveal Email/Phone |
9 | VP, Manufacturing and Supply Operations | Reveal Email/Phone |
10 | VP Clinical Development | Reveal Email/Phone |
FibroGen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is FibroGen?
FibroGen has developed the only commercially viable method known to produce human collagen and human gelatin in recombinant systems. FibroGen will exploit this technology by becoming both a bulk product supplier for the pharmaceutical and medical device industries as well as a developer and commercializer of injectable products, wound management products, and gelatin stabilizers. FibroGen's corporate collaborations include a partnership with Taisho Pharmaceutical Company of Japan to discover and develop human monoclonal antibody therapeutics for renal fibrosis and chronic transplant rejection.
keywords:Biotechnology
$188M
Total Funding
527
Number of Employees
$283.8M
Revenue (est)
-15%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
FibroGen News
A FibroGen Inc. investor filed suit in Delaware against current and former members of its board and management, claiming two of them sold...
356 IPF Patients Enrolled -. - Topline Data Anticipated Mid-2023 -. SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen,...
The securities action is In re FibroGen Inc. Securities Litigation, case number 3:21-cv-02623, in the U.S. District Court for the Northern...
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadus ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $94.4M | 531 | 4% | $162.5M |
#2 | $92.9M | 531 | 6% | N/A |
#3 | $96.4M | 532 | -10% | N/A |
#4 | $151.6M | 532 | 20% | N/A |
#5 | $96.4M | 532 | 16% | N/A |